BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38738528)

  • 1. Exploiting the ferroaddiction of pancreatic cancer cells using Fe-doped nanoparticles.
    Lomphithak T; Sae-Fung A; Sprio S; Tampieri A; Jitkaew S; Fadeel B
    Nanomedicine; 2024 Jan; 55():102714. PubMed ID: 38738528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.
    Li C; Yin X; Liu Z; Wang J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
    Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
    Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
    Müller F; Lim JKM; Bebber CM; Seidel E; Tishina S; Dahlhaus A; Stroh J; Beck J; Yapici FI; Nakayama K; Torres Fernández L; Brägelmann J; Leprivier G; von Karstedt S
    Cell Death Differ; 2023 Feb; 30(2):442-456. PubMed ID: 36443441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
    Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
    Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
    Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
    Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
    Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
    PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway.
    Dai E; Han L; Liu J; Xie Y; Zeh HJ; Kang R; Bai L; Tang D
    Nat Commun; 2020 Dec; 11(1):6339. PubMed ID: 33311482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
    Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
    PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer.
    Chen HD; Ye Z; Hu HF; Fan GX; Hu YH; Li Z; Li BR; Ji SR; Zhou CJ; Xu XW; Yu XJ; Qin Y
    Acta Pharmacol Sin; 2024 Apr; 45(4):844-856. PubMed ID: 38057506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53.
    Li J; Lama R; Galster SL; Inigo JR; Wu J; Chandra D; Chemler SR; Wang X
    Mol Cancer Ther; 2022 Apr; 21(4):535-545. PubMed ID: 35131878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidimensional screening of pancreatic cancer spheroids reveals vulnerabilities in mitotic and cell-matrix adhesion signaling that associate with metastatic progression and decreased patient survival.
    Aquino AF; Runa F; Shoma JF; Todd A; Wallace M; de Barros NR; Kelber JA
    Biochem Biophys Res Commun; 2024 Apr; 703():149575. PubMed ID: 38382357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of GRP78 inhibiting artesunate-induced ferroptosis in
    Wang K; Zhang Z; Wang M; Cao X; Qi J; Wang D; Gong A; Zhu H
    Drug Des Devel Ther; 2019; 13():2135-2144. PubMed ID: 31456633
    [No Abstract]   [Full Text] [Related]  

  • 17. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
    Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
    Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.
    Singh K; Pruski M; Bland R; Younes M; Guha S; Thosani N; Maitra A; Cash BD; McAllister F; Logsdon CD; Chang JT; Bailey-Lundberg JM
    Lab Invest; 2021 Feb; 101(2):177-192. PubMed ID: 33009500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.
    Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
    Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell death in pancreatic cancer: from pathogenesis to therapy.
    Chen X; Zeh HJ; Kang R; Kroemer G; Tang D
    Nat Rev Gastroenterol Hepatol; 2021 Nov; 18(11):804-823. PubMed ID: 34331036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.